ArticleOncotarget2020
Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours.
Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Bone metastases in lung carcinoids: current challenges in diagnosis and treatment -A systematic review of an unexplored issue.Endocrine · 2026Pooled it
- Efficacy and safety ofFrontiers in oncology · 2022Pooled it
- Analysis of clinical factors associated with incomplete standard protocolJapanese journal of radiology · 2025Article
- The South AustralianESMO gastrointestinal oncology · 2025Article
- Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.Journal of neuroendocrinology · 2025Review
- LutatheraPharmaceutics · 2023Review
- A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review.Translational lung cancer research · 2022Review
- Update to "Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors".The oncologist · 2022Article
- Efficacy and Safety ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Clinical Utility ofCancers · 2021Review
- Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy.Current oncology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeptide receptor radionuclide therapy (PRRT) is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours (GEP NETs), Although Phase III randomised clinical trial data is not available for NETs of other site of origin, in practice, PRRT is used more widely in clinical practice, based on its mechanism of targeting the somatostatin receptor. Use of PRRT for lung (bronchial) NET, specifically typical and atypical carcinoid (TC, AC), has been reported only in small retrospective case series. This multicentre study adds to the evidence regarding utility of PRRT for lung NETs. MATERIALS AND
methodsA retrospective chart review of patients with TC and AC who received
resultsForty-eight patients (32 AC, 15 TC, 1 unclassified) received a median of four
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.